Drug Profile
BPI 002
Alternative Names: BPI-002Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator BeyondSpring Pharmaceuticals
- Class Antineoplastics; Antivirals; Immunotherapies; Small molecules
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Colorectal cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (PO)
- 13 Mar 2020 BeyondSpring submits provisional U.S. patent application for BPI 002, for methods of treating viral infections, including COVID-2019 infections
- 13 Mar 2020 Preclinical trials in COVID-2019 infections in USA (PO)